Cite
HARVARD Citation
Linschoten, M. et al. (2020). Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet. 7 (4), pp. e295-e308. [Online].